Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Clinical Study to Evaluate the Efficacy and Safety of Matrix Pro Treatment

NCT06726122 · tracked via the Priya Life Science UK tracker
Phase
Not applicable
Started
2025-01-28
Last updated
2026-11-02

Condition(s) studied

Skin LaxityWrinkleSkin Condition

Investigational drug(s) / intervention(s)

Profound Matrix

Profound Matrix: Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).

Study summary

This is a non-randomized, multi-center, open-label, prospective clinical trial evaluating clinical treatments with the Matrix Pro Applicator for the improvement of facial and/or submental and neck laxity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
84 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Healthy female and male subjects between 18 to 84 years of age with Fitzpatrick Skin Type I - VI. 2. Willing to receive Profound Matrix treatments with Matrix Pro applicator 3. Able and willing to comply with the treatment/follow-up schedule and comply with all study (protocol) requirements. 4. Willing to provide signed, informed consent to participate in the study 5. Willing to have photographs and images taken of the treated areas to be used in evaluations, publications, presentations, and marketing materials (Subject identity will be masked). Exclusion Criteria: Any of the following will exclude the subject from the study: 1. Pregnant or planning to become pregnant, having given birth less than 3 months prior to enrollment into the study, and/or breast feeding 2. Pacemaker or internal defibrillator or any active electrical implant anywhere in the body 3. Superficial metal or other implants in the treatment area, except superficial dental implants, unless the implants can be removed or covered with rolled gauze during treatment 4. Skin cancer in the treatment area or history of melanoma 5. History of current cancer and/or subject has undergone chemotherapy within the last 12 months 6. Severe concurrent conditions, such as cardiac disorders 7. Impaired immune system or use of immunosuppressive medications, except for topical products and inhaler medications per investigator discretion 8. Herpes Simplex Virus (HSV) in the intended treatment area unless treated following a prophylactic regimen 9. Poorly controlled endocrine disorders such as poorly controlled diabetes 10. Active skin condition in the treatment area such as skin infection, sores, psoriasis, eczema, rash, or open wounds 11. History of abnormal wound healing, keloid, or hypertrophic scar formation, as well as very thin or fragile skin 12. History of collagen vascular disease or vasculitic disorders 13. Known allergy to medication to be used during treatments such as allergy to topical anesthetic (e.g., lidocaine) 14. History of systemic corticosteroid therapy in past six months 15. Tattoos or permanent makeup in the intended treatment area 16. Excessively tanned skin 17. Facelift in the last 12 months 18. Aesthetics treatments/procedures (e.g., facial resurfacing and deep chemical peeling) within the last 4 months within the intended treatment area 19. Neuromodulator injections (e.g., Botox®), collagen, non-permanent dermal filler, fat injections or other methods of augmentation with injected biomaterial in the intended treatment area within the last 3 months 20. Permanent synthetic fillers (e.g., silicone) in the intended treatment area 21. Absorbable facial threads within the last 12 months or non-absorbable facial threads within the intended treatment area 22. In the opinion of the Investigator, the subject is unwilling or unable to adhere to the study requirements or is otherwise unsuitable for study participation

Primary outcome measure(s)

  • Evaluation of change in facial, submentum, and neck laxity — From subject enrollment to completion of 3-month follow-up visit, up to 32 weeks.
    Evaluation of change in facial, submentum, and neck laxity based on correct identification of subject's post-treatment photograph by at least 2 of the 3 independent blinded reviewers.

Trial sites (3)

FacilityCityRegionStatus
Kliniek voor Esthetische Geneeskunde Amsterdam EK
Illuminate Skin & Wellness Clinic Kings Hill Kent
GHB Clinic London United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06726122 on ClinicalTrials.gov ↗ ← All trials in the UK